MapLight Therapeutics (MPLT) EPS (Basic) (2024 - 2025)
MapLight Therapeutics (MPLT) reported EPS (Basic) of -$9.35 for Q4 2025, up 68.08% on a YoY basis from -$5.57 in Q4 2024, and up 78.28% sequentially from -$43.06 in Q3 2025.
MapLight Therapeutics (MPLT) EPS (Basic) (2024 - 2025) Analysis & Trends
MapLight Therapeutics (MPLT) has 2 years of EPS (Basic) data on file, last reported at -$9.35 in Q4 2025.
- For the quarter ending Q4 2025, EPS (Basic) rose 68.08% year-over-year to -$9.35; the trailing twelve-month figure through Dec 2025 stood at -$18.08 (changed N/A YoY), and the FY2025 full-year result was -$20.3, up 83.57% from the prior year.
- EPS (Basic) climbed to -$9.35 in Q4 2025, from -$43.06 in the prior quarter.
- In the past five years, EPS (Basic) ranged from a high of -$9.35 in Q4 2025 to a low of -$43.06 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | 0.00 |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 0.00 |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 0.16 |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 4.06 |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 6.99 |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | 0.00 |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 5.90 |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -2.29 |
| 10 | MapLight Therapeutics | 314.07 Mn | 314.07 Mn | - | -9.35 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -9.35 |
| Sep 30, 2025 | -43.06 |
| Dec 31, 2024 | -29.31 |
| Sep 30, 2024 | -26.53 |